Outcome of Palliative Management of Malignant Large Bowel Obstruction w/Colorectal Stents or Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00140868 |
Recruitment Status :
Completed
First Posted : September 1, 2005
Last Update Posted : December 10, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Large Bowel Obstruction | Device: Luminal stents Procedure: Minimally Invasive Surgical Bowel Diversion | Phase 3 |
Large bowel obstruction is a common presentation among cancer patients, including those with non-colorectal malignancies. This study will evaluate patients with malignant large bowel obstruction who undergo palliative treatment with minimally invasive surgical diversion or endoscopic colorectal stent placement, in terms quality of life, symptom relief from bowel obstruction, and treatment-related complications. Assessments in changes in quality of life and symptom relief over time for each group will be done.
Traditionally malignant bowel obstruction is treated with surgery. In the last decade, creation of an ostomy can be completed with minimally invasive surgery, which reduces morbidity, mortality, and recovery time.wishes.
In the last several years, endoscopically inserted colorectal stents have emerged as an option for palliative treatment. This involves a simple procedure, often completed on an outpatient basis. This allows the intestinal lumen to remain open without the need for surgery.
- Primary Objective: is to compare the effect on quality of life of minimally invasive surgical bowel diversion and endoscopic stent placement in the treatment of malignant large bowel obstruction.
- Secondary Objectives: are to evaluate the symptom response (including abdominal pain, distention, bowel frequency and consistency, and nausea and emesis) and complication rate of treatment of malignant large bowel obstruction with endoscopic stent placement or minimally invasive surgical bowel diversion.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 180 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Official Title: | Outcome of Palliative Management of Malignant Large Bowel Obstruction With Colorectal Stents or Surgery |
Study Start Date : | December 2002 |
Actual Study Completion Date : | October 2006 |

- Primary objective: compare the effect on quality of life of minimally invasive surgical bowel diversion and endoscopic stent placement in the treatment of malignant large bowel obstruction.
- Secondary objectives:the symptom response and complication rate of treatment of malignant large bowel obstruction with endoscopic stent placement or minimally invasive surgical bowel diversion

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- men and women over 18 years of age
- presentation of large bowel obstruction based on clinical symptoms AND an imaging study.
- clinical symptoms: one of : progressive constipation, multiple small liquid bowel movements daily, abdominal distention, abdominal pain or nausea and vomiting.
- imaging study: one of: CT scan, barium or gastrograffin enema, flexible sigmoidoscopy or colonoscopy, showing any degree of colonic narrowing by tumor.
- large bowel obstruction due to stage IV colorectal cancer unresectable for cure OR unresectable local-regional colorectal cancer OR unresectable extra-colonic cancer (such as gastric, ovarian, prostate, pancreatic cancers).
- ability to give informed consent, indicating the investigational nature of this study in keeping with the policies of Memorial Sloan-Kettering Cancer Center.
Exclusion Criteria:
- presence of acute bowel perforation
- presence of a second synchronous large or small bowel obstruction site
- contra-indication to stent placement:
- obstruction greater than 12 cm in length (ie precluding treatment with one stent)
- obstruction located within 2 cm of dentate line
- contra-indication to laparoscopy:
- presence of MI, unstable angina, or CVA in the previous four weeks
- tense ascites
- uncorrectable coagulopathy
- prior abdominal surgery with known prohibitive adhesions
- prior PALLIATIVE treatment of malignant large bowel obstruction with surgery or stent
- inability to speak or read English, or other impairment which causes an inability to complete the quality of life questionnaires
- unable or unwilling to give informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00140868
United States, New York | |
Memorial Sloan-Kettering Cancer Center | |
New York, New York, United States, 10021 |
Principal Investigator: | Hans Gerdes, M.D. | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT00140868 |
Other Study ID Numbers: |
02-125 |
First Posted: | September 1, 2005 Key Record Dates |
Last Update Posted: | December 10, 2007 |
Last Verified: | December 2007 |
Colonic Pseudo-Obstruction Large bowel obstruction Stents Laparotomy |
Palliative Surgery Surgery, Palliative Palliative Therapy |
Intestinal Obstruction Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Phenobarbital Anticonvulsants Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs |
Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action GABA Modulators GABA Agents Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers Cytochrome P-450 CYP3A Inducers |